Academic Journal
Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
| العنوان: | Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis |
|---|---|
| المؤلفون: | A. V. Samtsov, V. R. Khairutdinov, A. L. Bakulev, A. A. Kubanov, A. E. Karamova, A. V. Artem’eva, T. V. Korotaeva |
| المصدر: | Vestnik Dermatologii i Venerologii, Vol 0, Iss 5, Pp 52-63 (2018) |
| بيانات النشر: | State Scientific Center of Dermatovenereology and Cosmetology, 2018. |
| سنة النشر: | 2018 |
| المجموعة: | LCC:Dermatology |
| مصطلحات موضوعية: | psoriasis, monoclonal antibody against interleukin-17, biological therapy, pasi 75, bcd-085, Dermatology, RL1-803 |
| الوصف: | Recent studies on psoriasis confirmed that interleukin-17 (IL-17) plays a crucial role in the progression of the disease. Inhibition of this cytokine leads to significant improvement in the course of the disease. Russian biotechnology company BIOCAD have developed an innovative drug, a monoclonal antibody against IL-17, BCD-085. The main objective of the phase II study was to determine the optimal therapeutic dose of BCD-085 in patients with moderate-tosevere plaque psoriasis. The efficacy, safety, and pharmacokinetics of the drug have also been investigated.Materials and methods The study was an international multicenter, comparative, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of multiple subcutaneous administration of various doses of BCD-085 to patients with moderate to severe plaque psoriasis. Patients were randomized into 4 groups in 1:1:1:1 ratio: group 1 received BCD-085 at a dose of 40 mg, group 2 – 80 mg, group 3 – 120 mg, and group 4 received placebo. Administration of BCD-085/placebo was performed subcutaneously on day 1 at weeks 0, 1, 2, and then on day 1 at weeks 4, 6, 8, 10.Results All studied doses of BCD-085 demonstrated significant superiority over placebo and high efficacy in the treatment of plaque psoriasis. PASI 75 at week 12 was reached by 92.68% of patients in group 3 (120 mg of BCD-085), 83.33% in group 2 (80 mg of BCD-085), 80.0% in group 1 (40 mg of BCD-085), and 23.08% in group 4 (placebo) (p < 0.0001). In the course of the study, the dose-dependent effect of the drug was demonstrated. The drug showed favorable safety profile (no cases of serious adverse events or early withdrawal due to adverse events, no cases of adverse events with 4 grade of severity according to CTCAE 4.03). According to the results of pharmacokinetics study, the drug is characterized by a linear increase in serum BCD-085 concentration, reaching its maximum by the end of the first week of observation, and by slow elimination.Conclusion BCD-085 showed high efficiency, more than 90% of patients reached PASI 75 by the 12th week of treatment, and a favorable safety profile. Based on the results of the phase II study, the optimal therapeutic dose was 120 mg. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English Russian |
| تدمد: | 0042-4609 2313-6294 |
| Relation: | https://www.vestnikdv.ru/jour/article/view/344; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294 |
| DOI: | 10.25208/0042-4609-2017-93-5-52-63 |
| URL الوصول: | https://doaj.org/article/ad95b195b540473996348322541ef657 |
| رقم الانضمام: | edsdoj.95b195b540473996348322541ef657 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 00424609 23136294 |
|---|---|
| DOI: | 10.25208/0042-4609-2017-93-5-52-63 |